You are here

Article Text

Article menu
Download PDFPDF
CASE REPORT
Tumefactive demyelination presenting during bevacizumab treatment

Summary

We report the emergence of tumefactive demyelination during treatment with intravitreal bevacizumab (Avastin). This is of particular significance given that bevacizumab is currently being assessed as a potential treatment option for neuromyelitis optica, another demyelinating condition.

https://doi.org/10.1136/bcr-2015-212173

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.